ripretinib
Selected indexed studies
- Ripretinib. (, 2012) [PMID:37956235]
- Ripretinib: First Approval. (Drugs, 2020) [PMID:32578014]
- USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition. (Adv Sci (Weinh), 2024) [PMID:38973363]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ripretinib. (2012) pubmed
- Ripretinib: First Approval. (2020) pubmed
- USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition. (2024) pubmed
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. (2020) pubmed
- Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. (2022) pubmed
- Ripretinib. (2006) pubmed
- Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. (2024) pubmed
- Ripretinib for gastrointestinal stromal tumours. (2021) pubmed
- Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. (2022) pubmed
- Ripretinib for the treatment of advanced gastrointestinal stromal tumor. (2021) pubmed